Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting (GlobeNewswire) - Jun 8, 2023 - "In addition, at the SNMMI Annual Meeting, Norman LaFrance, M.D., Chief Medical Officer, will present data from the ReSPECT-GBM and ReSPECT-LM clinical studies evaluating the Company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of recurrent glioblastoma (rGBM) and leptomeningeal metastases (LM), respectively."
P1/2 data • Glioblastoma • Oncology • Solid Tumor
|